Literature DB >> 19565332

Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures.

Ghaffar Muharram1, Emilie Le Rhun, Ingrid Loison, Pierre Wizla, Audrey Richard, Nathalie Martin, Annie Roussel, Agnes Begue, Patrick Devos, Marie-Christine Baranzelli, Jacques Bonneterre, Perrine Caillet-Fauquet, Dominique Stehelin.   

Abstract

Parvovirus H-1 (H-1 PV) preferentially replicates in malignant cells resulting in their death by cytolysis. It has often been considered a potential candidate for use in novel anticancer therapy. To evaluate its potential in a model of natural tumors, we assayed in vitro the effect exerted by H-1 PV on short-term cultures derived from breast tumor samples freshly excised from patients. Our results show that H-1 PV effectively kills tumor-derived cells, whereas normal tissue-derived cells showed no H-1 PV-induced cytopathic effects (CPE). We also determined that the H-1 PV sensitivity (up to 67% sensitive cultures) is related with the quantities of virus assayed. We further examined the expression and phosphorylation state of the parvoviral nonstructural protein 1 (NS1), known to be associated with parvoviruses-induced CPE. Both appear to be impaired in normal tissue-derived cells and resistant cultures. Finally, we show that H-1 PV sensitivity in cultures correlates significantly with higher tumor grades (Nottingham combined histologic grade 2 or 3). This report confirms that H-1 PV can efficiently induce CPE in primary breast tumor cells in vitro. It identifies tumor characteristics representing potential criteria for recruiting patients for clinical evaluation of H-1 PV antitumor effects.

Entities:  

Mesh:

Year:  2009        PMID: 19565332     DOI: 10.1007/s10549-009-0451-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

Review 1.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

2.  Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus.

Authors:  Olivier Moralès; Audrey Richard; Nathalie Martin; Dhafer Mrizak; Magalie Sénéchal; Céline Miroux; Véronique Pancré; Jean Rommelaere; Perrine Caillet-Fauquet; Yvan de Launoit; Nadira Delhem
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

Review 3.  Triple-negative breast cancer: new perspectives for novel therapies.

Authors:  Yashin A Mahamodhossen; Wei Liu; Zhou Rong-Rong
Journal:  Med Oncol       Date:  2013-07-04       Impact factor: 3.738

Review 4.  Oncolytic parvoviruses: from basic virology to clinical applications.

Authors:  Antonio Marchini; Serena Bonifati; Eleanor M Scott; Assia L Angelova; Jean Rommelaere
Journal:  Virol J       Date:  2015-01-29       Impact factor: 4.099

Review 5.  Current status of gene therapy for breast cancer: progress and challenges.

Authors:  Cian M McCrudden; Helen O McCarthy
Journal:  Appl Clin Genet       Date:  2014-11-10

6.  Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action.

Authors:  Kuikui Ge; Jinjiang Huang; Wei Wang; Meigang Gu; Xinchuan Dai; Yuqiang Xu; Hongyu Wu; Guodong Li; Hairong Lu; Jiang Zhong; Qingshan Huang
Journal:  Oncotarget       Date:  2017-01-24

Review 7.  Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.

Authors:  Assia L Angelova; Karsten Geletneky; Jürg P F Nüesch; Jean Rommelaere
Journal:  Front Bioeng Biotechnol       Date:  2015-04-22

Review 8.  Promising oncolytic agents for metastatic breast cancer treatment.

Authors:  James J Cody; Douglas R Hurst
Journal:  Oncolytic Virother       Date:  2015-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.